Opus Genetics IRD Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Opus Genetics in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Opus Genetics's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Opus Genetics's additional paid-in capital?
- Opus Genetics (IRD) reported additional paid-in capital of $208.28M in Q1 2026.
- How has Opus Genetics's additional paid-in capital changed year-over-year?
- Opus Genetics's additional paid-in capital increased by 36.8% year-over-year, from $152.26M to $208.28M.
- What is the long-term trend for Opus Genetics's additional paid-in capital?
- Over 5 years (2020 to 2025), Opus Genetics's additional paid-in capital has grown at a 60.4% compound annual growth rate (CAGR), from $19.21M to $203.93M.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.